vs
Side-by-side financial comparison of ALNYLAM PHARMACEUTICALS, INC. (ALNY) and NOVARTIS AG (NVS), based on the latest 10-Q / 10-K filings. Click either name above to swap in a different company.
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history — bar widths are scaled to the larger of the two companies so you can eyeball the size gap and growth trajectory without doing math. Quarters aligned by calendar period (report date) so offset fiscal years line up.
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $773.7M | — | ||
| Q1 25 | $594.2M | — | ||
| Q4 24 | $593.2M | — | ||
| Q3 24 | $500.9M | — | ||
| Q2 24 | $659.8M | — | ||
| Q1 24 | $494.3M | — |
| Q4 25 | $186.4M | — | ||
| Q3 25 | $251.1M | — | ||
| Q2 25 | $-66.3M | — | ||
| Q1 25 | $-57.5M | — | ||
| Q4 24 | $-83.8M | — | ||
| Q3 24 | $-111.6M | — | ||
| Q2 24 | $-16.9M | — | ||
| Q1 24 | $-65.9M | — |
| Q4 25 | 75.6% | — | ||
| Q3 25 | 84.2% | — | ||
| Q2 25 | 81.6% | — | ||
| Q1 25 | 88.2% | — | ||
| Q4 24 | 82.7% | — | ||
| Q3 24 | 83.6% | — | ||
| Q2 24 | 89.8% | — | ||
| Q1 24 | 89.0% | — |
| Q4 25 | 12.0% | — | ||
| Q3 25 | 29.5% | — | ||
| Q2 25 | -2.1% | — | ||
| Q1 25 | 3.0% | — | ||
| Q4 24 | -17.7% | — | ||
| Q3 24 | -15.4% | — | ||
| Q2 24 | 7.4% | — | ||
| Q1 24 | -8.8% | — |
| Q4 25 | 17.0% | — | ||
| Q3 25 | 20.1% | — | ||
| Q2 25 | -8.6% | — | ||
| Q1 25 | -9.7% | — | ||
| Q4 24 | -14.1% | — | ||
| Q3 24 | -22.3% | — | ||
| Q2 24 | -2.6% | — | ||
| Q1 24 | -13.3% | — |
| Q4 25 | $1.44 | — | ||
| Q3 25 | $1.84 | — | ||
| Q2 25 | $-0.51 | — | ||
| Q1 25 | $-0.44 | — | ||
| Q4 24 | $-0.66 | — | ||
| Q3 24 | $-0.87 | — | ||
| Q2 24 | $-0.13 | — | ||
| Q1 24 | $-0.52 | — |
Financial Flow Comparison
Sankey diagram of revenue → gross profit → operating profit → net profit for each company. Charts shown full-width and stacked so both segment hierarchies are readable side-by-side on desktop and mobile.
